AMS HP eNews Bulletin 29 June 2016


  Australasian Menopause Society  
Health Professionals eNews29 June 2016
  Welcome to AMS HP eNews for doctors and other healthcare professionals who have a special interest in women's health. The content covers information and resources relevant to menopause, midlife and the promotion of healthy ageing.


20th AMS Congress - Registration now open 

AMS Annual Congress  Fremantle - Western Australia 18-20 November 2016This year our Congress will be at the Esplanade Hotel in Fremantle, right in the heart of the art and cafe culture of the historic port city and close by to beaches, the Swan river and Rottnest Island. 


Register now and claim before EOFY!

Earlybird registration is open now so you can claim a tax deduction before the end of the financial year. 


Submit an abstract!

AMS invites the submission of papers on original work for consideration for the Congress Program. Authors are invited to submit abstracts for 15 minute oral and/or poster presentations for consideration by the AMS Scientific Program Committee. 


Abstracts may be submitted on any topic relevant to the menopause and its treatment. A link to Guidelines in Preparing and formatting your abstract are available from the AMS Website.


Abstract submissions close 13 August 2016



Predicting women at risk for rapid bone loss  

bone healthResearchers have developed an index to better predict which women may experience faster bone loss across the menopause transition.


Osteoporosis is often referred to as a "silent" disease because individuals who have it experience few noticeable symptoms. The progressive condition occurs when bones grow structurally weak and become more likely to fracture or break. 


The researchers call the index a Bone Balance Index. The index was most useful for predicting bone loss in the bones of the spine. To create the index, the researchers used data from a cohort of women as they went through menopause. Women are prone to bone loss during the menopausal transition. The 685 women, who participated in the Study of Women's Health across the Nation, were between the ages of 42 and 52. The women were either premenopausal or in early perimenopause when they enrolled in the study, and all of the participants included in this analysis had their final menstrual period during the follow-up portion of the study.



Bone fracture risk assessment  



An Australian-first bone health self-assessment tool designed to help consumers understand their bone fracture risk has been produced by Osteoporosis Australia and Garvan Institute of Medical Research.


The processs involves completing the assessment to generate a report which can be saved for discussion with the patient's doctor.   



Sexual difficulties in the menopause - updated Information Sheet

sexual difficulties

Sexual response and therefore sexual difficulty can refer to desire, arousal, orgasm or pain with intercourse. Although these are classified as separate elements in sexual response, they become inextricably linked when dysfunction occurs. A clinical history should attempt to define what may be the initiating and maintaining problems.


Low libido refers to diminished desire for sex. When clinically a problem it is referred to as hypoactive sexual desire disorder (HSDD). Low libido is the most common sexual concern reported by women and is often inseparable from diminished capacity to become aroused. More recently HSDD has been merged with female sexual arousal disorders and re-named 'female sexual interest-arousal disorder' (FSIAD), which remains primarily based on sexual desire (1). It is still reasonable to talk about HSDD or simply loss of libido. Other common sexual concerns for women include delayed / inability to achieve an orgasm and vaginal pain, often due to vaginal dryness.


Sexual difficulties can be life-long or recently acquired, but they are a common presentation at the menopause. They may also be situational (limited to certain types of stimulation, situations, or partners) or generalized...




Menopause Essentials Update for Health Professionals:
28 July 2016

Menopause Essentials Update for Health Professionals  28 July 2016 - Hotel Grand Chancellor, Hobart

This workshop is aimed at all GPs, specialists and allied health workers who are seeking a comprehensive update in the field of menopause.


Prof Bronwyn Stuckey and Dr Jane Elliott will be presenting and providing case studies on the following topics:


Menopause: What is it? 
Prof Bronwyn Stuckey

How to manage menopause 
Dr Jane Elliott

Risks and benefits of HRT
Prof Bronwyn Stuckey

Troubleshooting HRT, low libido and testosterone
Dr Jane Elliott  


About the Speakers:

Professor Bronwyn Stuckey BA MBBS FRACP is President of the Australasian Menopause Society. Bronwyn is an endocrinologist with a clinical and research interest in reproductive endocrinology. She is Consultant Endocrinologist in the Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia and Clinical Professor in the School of Medicine and Pharmacology, University of Western Australia. She is also the Medical Director of the Keogh Institute for Medical Research which conducts both clinics and research for both men and women. The focus of her research and that of the Institute is on the interface between reproduction and reproductive hormones and metabolism.


Dr Jane Elliott, MBBS, is a Past President and a Life Member of the Australasian Menopause Society. Jane is a general practitioner with a longstanding commitment in women’s health especially menopause and midlife women’s health. She is a Clinical Lecturer in the Discipline of Obstetrics and Gynaecology at the University of Adelaide and a member of the Medical and Scientific Committee of Osteoporosis Australia.


Venue: Hotel Grand Chancellor, Hobart


Registration: $50 for AMS Members, $75 for Non­‐members


Registration is now open here...



Join AMS for Member's only content

See exclusive commentary on studies such as:  


NAMS Information Update on Fractional Laser Treatment for VVA

Although this technology is marketed as being FDA approved for broad indications, it is not approved or cleared by FDA for the specific indication of treating VVA. To further clarify this point, in May 2016, the American Congress of Obstetricians and Gynecologists (ACOG) issued a Position Statement, Fractional Laser Treatment of Vulvovaginal Atrophy and US Food and Drug Administration Clearance...


Hormone therapy and large bowel cancer revisited

Colorectal cancer is among the most common malignancies in the Western world. Many studies have investigated a potential association between postmenopausal hormone therapy (HT) and risk for colorectal cancer. The latest study on this topic has just appeared...


Eating disorders in midlife women 

In a recent paper, the evidence is discussed that suggests perimenopause may indeed be a vulnerable period for the development or redevelopment of an eating disorder for midlife women...


Cardiovascular results from the ELITE stud

The results from the ELITE (Early versus Late Intervention Trial with Estradiol) study have been long awaited because of its desired methodology...


2016 ams congress 1

  Australasian Menopause Society
PO Box 511, Inverloch VIC 3996
Tel: +61 3 9428 8738

  Join the Australasian Menopause Society  
Forward this email to a friend